Replimune Group Inc
REPLHealthcare|Biotechnology|USA
$10.99
-0.12 (-1.08%)
Tangible Book
$2.01
Earnings Power
$1.15
Clinical Trials (17)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT06264180 VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3] | Advanced Melanoma | P3 | Recruiting | 400 | RCT, Open-label | Vusolimogene Oderparepvec, Nivolumab, Nivolumab + Relatlimab, Pembrolizumab, Single-agent chemotherapy |
| NCT06581406 A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma | Metastatic Uveal Melanoma | P2P3 | Recruiting | 280 | RCT, Open-label | RP2, Ipilimumab, Nivolumab |
| NCT06898970 Intratumoral Vusolimogene Oderparepvec (VO) in Combination With Pembrolizumab for Angiosarcoma | Angiosarcoma, Angiosarcoma, Adult | P2 | Active | 18 | Open-label | Vusolimogene Oderparepvec (VO), Pembrolizumab |
| NCT05733598 Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC | Hepatocellular Carcinoma, Biliary Tract Cancer | P2 | Recruiting | 60 | Open-label | RP2, Bevacizumab, Atezolizumab, Durvalumab, RP2 Monotherapy |
| NCT04349436 Study to Investigate the Efficacy and Safety of RP1 in Adult Patients With Organ Transplants and Advanced Skin Malignancies | Merkel Cell Carcinoma, Basal Cell Carcinoma | P1P2 | Active | 69 | Open-label | RP1, intra-tumoral injection, oncolytic virus |
| NCT03767348 Study of RP1 Monotherapy and RP1 in Combination With Nivolumab (IGNYTE) | Non-Small Cell Lung Cancer (NSCLC), Microsatellite Instability-High (MSI-H) | P2 | Active | 340 | Open-label | RP1, nivolumab |
| NCT06623110 Phase II Study of RP2 as Immunoprevention in High-Risk Oral Precancerous Disease | High-Risk Oral Precancerous Disease | P2 | Recruiting | 25 | Open-label | RP2 Injection |
| NCT04050436 Study Evaluating Cemiplimab Alone and Combined With RP1 in Treating Advanced Squamous Skin Cancer | Cutaneous Squamous Cell Carcinoma, Advanced Cutaneous Squamous Cell Carcinoma | P2 | Active | 231 | RCT, Open-label | Cemiplimab, RP1 |
| NCT04336241 Study of RP2 Monotherapy and RP2 in Combination With Nivolumab in Patients With Solid Tumors | Cancer | P1 | Active | 36 | Open-label | RP2, nivolumab |
| NCT04735978 Study of RP3 Monotherapy and RP3 in Combination With Nivolumab in Patients With Solid Tumours | Advanced Solid Tumor | P1 | Active | 123 | Open-label | RP3, Nivolumab |
| NCT06216938 RP1 in Primary Melanoma to Reduce the Risk of Sentinel Lymph Node Metastasis | Melanoma | Early P1 | Recruiting | 25 | Open-label | Vusolimogene oderparepvec (RP1) |
| NCT06887348 A Study to Assess the Long-term Safety Outcomes in Patients Previously Treated With RP1, RP2, or RP3 | Melanoma, Metastatic Melanoma | Recruiting | 50 | — | — | |
| NCT05743270 Study of RP3 in Combination With Nivolumab and Other Therapy in Patients With Locoregionally Advanced or Recurrent SCCHN | Squamous Cell Carcinoma of Head and Neck, Locally Advanced Head and Neck Squamous Cell Carcinoma | P2 | Withdrawn | — | RCT, Open-label | RP3, nivolumab |
| NCT06067061 "neoBREASTIM": Atezolizumab Plus RP1 Oncolytic Immunotherapy in the NeoAdjuvant Setting of Triple-Negative Breast Cancer | Triple Negative Breast Neoplasms | P1P2 | Terminated | 2 | Open-label | — |
| NCT05733611 RP2/RP3 in Combination With Atezolizumab and Bevacizumab for the Treatment of Patients With CRC | Refractory Metastatic Colorectal Cancer, pMMR | P2 | Terminated | 5 | Open-label | RP2, RP3, atezolizumab, bevacizumab |
| NCT07059611 Neoadjuvant Intra-tumoral RP2 and FLOT in Gastroesophageal Adenocarcinoma | Gastric Adenocarcinoma, Esophageal Adenocarcinoma | P2 | Not Yet Recruiting | 34 | Open-label | RP2, Pegfilgrastim, Filgrastim |
| NCT06590480 An Expanded Access Program for VO (RP1) in Combination With Nivolumab in Patients With Advanced Melanoma | Advanced Melanoma | NO_LONGER_AVAILABLE | — | — | RP1, Nivolumab |